Genes that modulate hepatic fat accumulation and retinol metabolism [i.e., transmembrane 6 superfamily member 2 (TM6SF2), variants of patatin-like phospholipase domain which contain protein 3 (PNPLA3), membrane-bound O-acyltransferase domain containing 7 (MBOAT7), hydroxysteroid 17β-dehydrogenase (HSD17B13), and glucokinase regulator (GCKR)] (9) and the deregulation of microRNAs are known to influence NAFLD development and progression (18). The gene discussed is TM6SF2; the disease is metabolic dysfunction-associated steatotic liver disease.